The offer of $48 per Array share represents a premium of about 62% to the stock’s close on Friday. Array’s shares surged 56% in light premarket trade.
Pfizer to buy cancer drug developer Array for $10.64 billion
More from Industry NewsMore posts in Industry News »
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference
- India initiates antidumping probe on certain type of steel from Brazil, China, Germany
- BDR Pharma receives DGCI nod for its generic drug BIAPENEM
- AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs